We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
CIPLA DEFERASIROX, DEFERACIP, DESIROX (Cipla Australia Pty Ltd)
Product name
CIPLA DEFERASIROX, DEFERACIP, DESIROX
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
152 (255 working days)
Active ingredients
deferasirox
Registration type
New generic medicine
Indication
CIPLA DEFERASIROX, DEFERACIP, DESIROX (tablet) is indicated for the treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adults and paediatric patients 6 years and older.CIPLA DEFERASIROX, DEFERACIP, DESIROX is also indicated for the treatment of chronic iron overload in paediatric patients aged 2 to 5 years who are unable to take desferrioxamine therapy or in whom desferrioxamine has proven ineffective.
CIPLA DEFERASIROX, DEFERACIP, DESIROX is also indicated for the treatment of chronic iron overload in patients with non-transfusiondependent thalassemia syndromes aged 10 years and older.